Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2318]

Transforming cancer care in India: The Access Cancer Care Initiative

Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran

Transforming cancer care in India: The Access Cancer Care Initiative ( Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran )

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC

Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC ( Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas )

Key insights from head and neck research at ASCO 2025

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA

Key insights from head and neck research at ASCO 2025 ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC ( Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

Ordronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2...

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy

Ordronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory...

Dr Anthony Stein - City of Hope, Duarte, USA

$Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia ( Dr Anthony Stein - City of Hope, Duarte, USA )$

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with...

Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM ( Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France )

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared...

Dr Moritz Fürstenau - University of Cologne, Cologne, Germany

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies ( Dr Moritz Fürstenau - University of Cologne, Cologne, Germany )

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy...

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL ( Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

More from ecancer